Clinical Trial Update: A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of a selective androgen receptor modulator for symptom management in prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Selective androgen receptor modulator (SARM) studied in trial NCT02499497

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-28